Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice

European Journal of Pharmacology

Volumn 520, Issue 1-3, 2005, Pages 164-171

  Ueda, Yoshifumi ^a   Miyagawa, Naoki ^a   Matsui, Tomoko ^a   Kaya, Tetsudo ^a   Iwamura, Hiroyuki ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Agonist; Cannabinoid CB2 receptor; Ear swelling; Inverse agonist; JTE 907

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AMIDE; CANNABINOID RECEPTOR ANTAGONIST; JTE 907; MESSENGER RNA; METHANOL DERIVATIVE; N (BENZO[1,3]DIOXO 5 YLMETHYL) 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLONE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EDEMA; FEMALE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SKIN INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; AREA UNDER CURVE; BORNANES; CANNABINOIDS; DINITROFLUOROBENZENE; DIOXOLES; DISEASE MODELS, ANIMAL; DRUG ERUPTIONS; EAR, EXTERNAL; FEMALE; INDOMETHACIN; INFLAMMATION; LYMPH NODES; MICE; MICE, INBRED BALB C; PYRAZOLES; QUINOLONES; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TIME FACTORS;

EID: 25444464434     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.08.013     Document Type: Article

References (39)

1. T. Bisogno, N. Sepe, D. Melck, S. Maurelli, L. De Petrocellis, and V. Di Marzo Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells Biochem. J. 322 Pt 2 1997 671 677
2. Y.H. Chang, S.T. Lee, and W.W. Lin Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids J. Cell. Biochem. 81 2001 715 723
3. N. Clayton, F.H. Marshall, C. Bountra, and C.T. O'Shaughnessy CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain Pain 96 2002 253 260
4. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
5. V. Di Marzo, T. Bisogno, T. Sugiura, D. Melck, and L. De Petrocellis The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide Biochem. J. 331 Pt 1 1998 15 19
6. V. Di Marzo, T. Bisogno, L. De Petrocellis, D. Melck, P. Orlando, J.A. Wagner, and G. Kunos Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages Eur. J. Biochem. 264 1999 258 267
7. L. Facci, R. Dal Toso, S. Romanello, A. Buriani, S.D. Skaper, and A. Leon Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide Proc. Natl. Acad. Sci. U. S. A. 92 1995 3376 3380
8. R. Gallily, A. Breuer, and R. Mechoulam 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice Eur. J. Pharmacol. 406 2000 R5 R7
9. W. Gonsiorek, C. Lunn, X. Fan, S. Narula, D. Lundell, and R.W. Hipkin Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide Mol. Pharmacol. 57 2000 1045 1050
10. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R.G. Pertwee, R.A. Ross, R. Mechoulam, and E. Fride HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. U. S. A. 96 1999 14228 14233
11. C.J. Hillard Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol Prostaglandins Other Lipid Mediat. 61 2000 3 18
12. H. Iwamura, H. Suzuki, Y. Ueda, T. Kaya, and T. Inaba In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor J. Pharmacol. Exp. Ther. 296 2001 420 425
13. M.A. Jorda, S.E. Verbakel, P.J. Valk, Y.V. Vankan-Berkhoudt, M. Maccarrone, A. Finazzi-Agro, B. Lowenberg, and R. Delwel Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol Blood 99 2002 2786 2793
14. S. Kishimoto, M. Gokoh, S. Oka, M. Muramatsu, T. Kajiwara, K. Waku, and T. Sugiura 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism J. Biol. Chem. 278 2003 24469 24475
15. M. Lee, K.H. Yang, and N.E. Kaminski Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes J. Pharmacol. Exp. Ther. 275 1995 529 536
16. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
17. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, D.R. Compton, R.G. Pertwee, G. Griffin, M. Bayewitch, J. Barg, and Z. Vogel Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
18. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
19. A.G. Nackley, A. Makriyannis, and A.G. Hohmann Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation Neuroscience 119 2003 747 757
20. A.G. Nackley, A.M. Zvonok, A. Makriyannis, and A.G. Hohmann Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation J. Neurophysiol. 92 2004 3562 3574
21. H. Nagai, H. Hiyama, A. Matsuo, Y. Ueda, N. Inagaki, and K. Kawada FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice J. Pharmacol. Exp. Ther. 283 1997 321 327
22. H. Nagai, A. Matsuo, H. Hiyama, N. Inagaki, and K. Kawada Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten J. Allergy Clin. Immunol. 100 1997 S39 S44
23. H. Nagai, Y. Ueda, T. Ochi, Y. Hirano, H. Tanaka, N. Inagaki, and K. Kawada Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice Br. J. Pharmacol. 129 2000 299 306
24. S. Oka, S. Ikeda, S. Kishimoto, M. Gokoh, S. Yanagimoto, K. Waku, and T. Sugiura 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils J. Leukoc. Biol. 76 2004 1002 1009
25. S. Oka, S. Yanagimoto, S. Ikeda, M. Gokoh, S. Kishimoto, K. Waku, Y. Ishima, and T. Sugiura Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear J. Biol. Chem. 280 2005 18488 18497
26. R.G. Pertwee Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development Expert Opin. Investig. Drugs 9 2000 1553 1571
27. D.A. Pettit, D.L. Anders, M.P. Harrison, and G.A. Cabral Cannabinoid receptor expression in immune cells Adv. Exp. Med. Biol. 402 1996 119 129
28. D. Piomelli, A. Giuffrida, A. Calignano, and F. Rodriguez de Fonseca The endocannabinoid system as a target for therapeutic drugs Trends Pharmacol. Sci. 21 2000 218 224
29. A.C. Porter, and C.C. Felder The endocannabinoid nervous system: unique opportunities for therapeutic intervention Pharmacol. Ther. 90 2001 45 60
30. A. Quartilho, H.P. Mata, M.M. Ibrahim, T.W. Vanderah, F. Porreca, A. Makriyannis, and T.P. Malan Jr. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors Anesthesiology 99 2003 955 960
31. M. Rinaldi-Carmona, F. Barth, J. Millan, J.M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, M. Portier, D. Shire, J.C. Breliere, and G.L. Le Fur SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
32. A.R. Schatz, M. Lee, R.B. Condie, J.T. Pulaski, and N.E. Kaminski Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system Toxicol. Appl. Pharmacol. 142 1997 278 287
33. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 215 1995 89 97
34. T. Sugiura, T. Kodaka, S. Nakane, S. Kishimoto, S. Kondo, and K. Waku Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem. Biophys. Res. Commun. 243 1998 838 843
35. T. Sugiura, T. Kodaka, S. Nakane, T. Miyashita, S. Kondo, Y. Suhara, H. Takayama, K. Waku, C. Seki, N. Baba, and Y. Ishima Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds J. Biol. Chem. 274 1999 2794 2801
36. T. Sugiura, S. Kondo, S. Kishimoto, T. Miyashita, S. Nakane, T. Kodaka, Y. Suhara, H. Takayama, and K. Waku Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells J. Biol. Chem. 275 2000 605 612
37. Y. Ueda, T. Sone, N. Inagaki, and H. Nagai Effects of prednisolone on the cutaneous reaction and skin barrier function in mice treated with a hapten Biol. Pharm. Bull. 26 2003 618 621
38. K. Varga, J.A. Wagner, D.T. Bridgen, and G. Kunos Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension FASEB J. 12 1998 1035 1044
39. J.M. Young, D.A. Spires, C.J. Bedord, B. Wagner, S.J. Ballaron, and L.M. De Young The mouse ear inflammatory response to topical arachidonic acid J. Invest. Dermatol. 82 1984 367 371